European Archives - Page 589 of 1190 - European Medical Journal

EMJ Innovations 6.1

Scientific Highlights in Innovation

COVID-19 took the world by surprise in late 2019, pushing scientists to study the virus extensively and create an effective vaccine.

Interview: Christina Furtado

Christina Furtado Mental Health and Wellness Specialist, guard.me International Insurance; Master of Arts in Counselling Psychology (MACP); practising member of the Canadian Psychological Association (CPA) and Ontario Association of Mental Health Professionals (OAMP).

EMJ Innovations 6.1

Augmented Reality for Identifying Botulinum Toxin Injection Sites

Facial botulinum toxin injection is a skill developed with experience. Inaccurate injections of the toxin can cause local complications as…

EMJ Innovations 6.1

The Evolving Evidence Base of Implantable Cardiac Defibrillators: Past, Present, and Future

This review describes the evidence that forms the foundation for the use of an implantable cardiac defibrillator (ICD)…

EMJ Innovations 6.1

Current Therapy in Inflammatory Bowel Disease: Why and How We Need to Change?

Inflammatory bowel disease (IBD) represents a group of idiopathic chronic inflammatory disorders of the gastrointestinal tract, including…

EMJ Innovations 6.1

Fertility and Pregnancy Outcomes after High-Intensity Focused Ultrasound Ablation for Uterine Fibroids and Adenomyosis: A Review

Uterine fibroids and adenomyosis are common among reproductive-age females. Uterine fibroids, particularly large submucosal and intramural…

Challenges in diagnosis and management of uncomplicated urinary tract infection (uUTI) episodes caused by antibiotic resistant pathogens, including those with a history of recurrence

We explore the challenges surrounding the diagnosis and management of resistant pathogens which cause UTIs and recurrent UTIs

REPRO

Heterotopic Pregnancy after In Vitro Fertilisation and Embryo Transfer Post-unilateral Salpingectomy: A Case Report and Literature Review

Infertility is one of the major health concerns faced by individuals globally. The 2021 United Nations (UN) World Population Prospects…

Aviptadil: Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in Patients with COVID-19 with Severe Respiratory Failure

Aviptadil has already proved to be an effective option in the treatment of severe respiratory failures due to sepsis and other related lung injuries. The final results from a recently completed trial, as well as all currently ongoing trials, will clarify the class effect of this drug in the treatment of COVID-19 in future days.

Ripples of change in R&D

How can pharma companies improve inclusivity across their R&D cycles?